Balancing Solid CF Revenue With Kidney Pipeline Uncertainty: Why Stringer Maintains a Hold on Vertex

Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today.

Joseph Stringer has given his Hold rating due to a combination of factors tied to Vertex’s current performance and outlook. Quarterly revenue met both his and the Street’s expectations, yet earnings per share came in softer than projected, and the company’s 2026 sales forecast, while consistent with consensus, fell short of his prior estimates.

At the same time, he sees the cystic fibrosis portfolio as a reliable revenue base, but notes that the key debate now is the pace and scale of diversification into new kidney disease assets such as povetacicept and inaxaplin. He views povetacicept as a potentially meaningful growth driver with multi‑billion dollar upside if upcoming Phase 3 IgA nephropathy data are successful, making a positive readout a potential catalyst, but until that risk is resolved, he believes a Hold stance remains appropriate despite growing optimism.

In another report released today, Stifel Nicolaus also assigned a Hold rating to the stock with a $466.00 price target.